GlassScriptPhysician profile
Christopher Mcneill
NPI 1952756827
$7,178.31
in general payments reported to CMS, 2019-2025
47 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $217 · 2021: $981 · 2022: $1,207 · 2023: $1,891 · 2024: $1,636 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,760 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,760.10 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $944.30 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $872.97 | 2021-2025 | |
| Glaxosmithkline, LLC. | $739.46 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $469.28 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $450.06 | 2020-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.25 | 2020-2025 | Xifaxan |
| Lilly USA, LLC | $393.59 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $354.64 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $306.71 | 2023-2025 | |
| Exact Sciences Corporation | $218.97 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $160.61 | 2020-2025 | Repatha, Otezla, Evenity |
| Immunitybio, INC. | $146.31 | 2025 | |
| Merck Sharp & Dohme LLC | $138.12 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $117.72 | 2023-2024 | Ams 700, Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $107.79 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.